# Verdiva Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/verdiva-bio

- Industry: Biotechnology
- Headquarters: London, UK
- Website: verdivabio.com
- Total disclosed funding: $411M
- Latest round: Series A (Dec 10, 2024)
- Investors on record: 7

## About

Based in London, UK, and founded in 2024, Verdiva Bio Limited operates as developer of biopharmaceuticals focused on therapies for obesity and cardiometabolic disorders. In January 2025, Verdiva Bio Limited raised USD 411 million in series A funding co-led by investors Forbion and General Atlantic, with participation from other investors RA Capital Management, OrbiMed Advisors, Logos Capital, Lilly Asia Ventures and LYFE Capital. The firm as of January 2025, is led by its co-founders, Khurem Farooq (CEO) and Mark Pruzanski (Chairman of the board).

The company’s flagship product, VRB-101, is an oral GLP-1 receptor agonist designed for once-weekly dosing, which has shown efficacy in clinical trials. Complementing this, Verdiva Bio is advancing several other products, including VRB-103, a dual amylin and calcitonin receptor agonist in preclinical development, which will serve as both a monotherapy and in combination with VRB-101. This portfolio addresses significant unmet medical needs and targets the end users consisting of patients suffering from obesity and cardiometabolic disorders. 

The company plans to utilize the January 2025 funding to develop a portfolio of oral and injectable treatments.

## Funding rounds

- Series A, Dec 10, 2024, $411M — OrbiMed Advisors, General Atlantic, Forbion, Lilly Asia Ventures, RA Capital Management, LYFE Capital, Logos Capital

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- General Atlantic (https://capitalatlas.ai/funds/general-atlantic) — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- LYFE Capital — Series A
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series A